JMJD1C-IN-1

Overview

JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C ( IC 50 = 0.59 μM, K d = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay ( IC 50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer , Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer ). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells.

Application

Products | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Histone Demethylase | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > STAT

Product Information

• Catalog No.: HY-162275
• CAS No.: 861224-48-8
• Molecular Formula: C16H15NO4S
• Molecular Weight: 317.36
• Purity: 99.96%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1 mg/mL (3.15 mM); Clear solution
• Availability: In-stock

Source

Original product source